Dashboard
Manage Tickers

ELVN Enliven Therapeutics, Inc.

Nasdaq www.enliventherapeutics.com


$ 17.65 $ -0.67 (-3.66 %)    

Friday, 07-Nov-2025 15:59:54 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 17.63
$ 18.17
$ 16.10 x 14,200
$ 18.50 x 1
$ 16.80 - $ 18.40
$ 13.30 - $ 29.40
578,149
na
1.04B
$ 0.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 02-10-2023 12-31-2022 10-K
12 10-25-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-06-2022 03-31-2022 10-Q
15 03-15-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-05-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
11/03/2025 17:05:47

enlivens-elvn-001-shows-anti-cml-activity-in-patients-with-atypical-fusion-transcripts-will-present-data-from-the-ongoing-enable-phase-1a1b-clinical-trial-of-elvn-001-on-a-subset-of-chronic-myeloid-leukemiapatients-at-the-ash-2025-annual-meeting
Enliven's ELVN-001 Shows Anti-CML Activity...
11/03/2025 14:09:53

ELVN-001 demonstrates encouraging anti-CML activity in heavily pretreated patients with atypical fusion transcriptsGrowing unme...

enliven-therapeutics--files-for-mixed-shelf-size-not-disclosed
Enliven Therapeutics Files For Mixed Shel...
08/13/2025 21:11:51

-SEC Filing

enliven-therapeutics-q2-eps-049-beats-054-estimate
Enliven Therapeutics Q2 EPS $(0.49) Beats ...
08/13/2025 20:25:55

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of ...

meta-to-rally-around-3-here-are-10-top-analyst-forecasts-for-wednesday
Meta To Rally Around 3%? Here Are 10 Top A...
07/02/2025 13:05:08

hc-wainwright--co-maintains-buy-on-enliven-therapeutics-raises-price-target-to-48
HC Wainwright & Co. Maintains Buy on Enliv...
07/02/2025 10:47:46

HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price ta...

goldman-sachs-initiates-coverage-on-enliven-therapeutics-with-buy-rating-announces-price-target-of-37
Goldman Sachs Initiates Coverage On Enlive...
06/16/2025 13:38:01

Goldman Sachs analyst Salveen Richter initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announc...

baird-maintains-outperform-on-enliven-therapeutics-raises-price-target-to-52
Baird Maintains Outperform on Enliven Ther...
06/16/2025 13:19:38

Baird analyst Colleen Kusy maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
06/13/2025 17:06:07

enliven-therapeutics-prices-underwritten-public-offering-of-839m-shares-at-1966shr
Enliven Therapeutics Prices Underwritten P...
06/13/2025 13:33:35

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the di...

enliven-therapeutics-launches-200m-public-offering-with-option-for-30m-upsize
Enliven Therapeutics Launches $200M Public...
06/13/2025 10:16:30

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the di...

enliven-therapeutics-announced-updated-data-from-phase-1-enable-clinical-trial-evaluating-elvn-001-in-patients-with-chronic-myeloid-leukemia-in-an-oral-presentation-at-european-hematology-association-2025-congress
Enliven Therapeutics Announced Updated Dat...
06/13/2025 10:06:14

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achievingMMR by 24 weeks, which cont...

jones-trading-maintains-buy-on-enliven-therapeutics-lowers-price-target-to-27
Jones Trading Maintains Buy on Enliven The...
05/16/2025 20:36:05

Jones Trading analyst Soumit Roy maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lowers the price target from $3...

hc-wainwright--co-maintains-buy-on-enliven-therapeutics-raises-price-target-to-40
HC Wainwright & Co. Maintains Buy on Enliv...
05/15/2025 11:23:02

HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price ta...

enliven-therapeutics-q1-eps-057-misses-049-estimate
Enliven Therapeutics Q1 EPS $(0.57) Misses...
05/14/2025 20:35:26

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate o...

enliven-therapeutics-announces-updated-data-from-phase-1-enable-clinical-trial-evaluating-elvn-001-in-patients-with-cml-in-abstract-accepted-for-oral-presentation-at-eha-2025-congress
Enliven Therapeutics Announces Updated Dat...
05/14/2025 13:59:13

Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which cont...

greenbrier-rpm-international-cvrx-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Greenbrier, RPM International, CVRx And Ot...
04/08/2025 12:35:36

hc-wainwright--co-maintains-buy-on-enliven-therapeutics-raises-price-target-to-39
HC Wainwright & Co. Maintains Buy on Enliv...
03/21/2025 11:52:23

HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price ta...

enliven-therapeutics-q4-2024-gaap-eps-046-beats-052-estimate
Enliven Therapeutics Q4 2024 GAAP EPS $(0....
03/13/2025 20:22:44

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of ...

btig-initiates-coverage-on-enliven-therapeutics-with-buy-rating-announces-price-target-of-42
BTIG Initiates Coverage On Enliven Therape...
12/13/2024 11:56:13

BTIG analyst Justin Zelin initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announces Price Tar...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION